G6PD and G6PD deficiency: To note that for recommendation #2, the KSA panel considered the increased risk of hemolysis with the use of hydroxychloroquine (HCQ) in the KSA due to the relatively high prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in this population [21].